Elevance Health Inc (ELV)
Official siteHEALTHCARE • HEALTHCARE PLANS • NYSE
Market Cap: $92.84B
Last updated: Nov 17, 2026 at 11:05 AM ET
Elevance Health Inc (ELV) Earnings: Report Dates and Results
Elevance Health (ELV) is expected to report earnings on Jan 26, 2027. In the quarter ended Sep 30, 2026, Elevance Health reported EPS of $6.99, above the $4.66 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ELV has an expected report date of Jan 26, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 37.5% below the $3.33 reported for the quarter ended Dec 31, 2025.
ELV Earnings Call
The latest ELV earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, ELV beat 35, missed 4 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $51.43B, up 1.4% from $50.71B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $6.99 | $4.66 | $4.55 - $4.99 | +50.00% | Beat | +15.9% | 19 | 3 up, 1 down | Oct 21, 2026 | $51.43B |
| Jun 30, 2026 | $7.45 | $6.18 | $6.06 - $6.73 | +20.55% | Beat | -15.7% | 20 | 0 up, 0 down | Jul 15, 2026 | $50.47B |
| Mar 31, 2026 | $12.58 | $10.81 | $6.53 - $11.28 | +16.37% | Beat | +5.1% | 20 | 2 up, 1 down | Apr 22, 2026 | $50.18B |
| Dec 31, 2025 | $3.33 | $3.09 | $2.85 - $3.32 | +7.77% | Beat | -13.3% | 20 | 1 up, 2 down | Jan 28, 2026 | $49.75B |
| Sep 30, 2025 | $6.03 | $4.94 | $4.47 - $5.94 | +22.06% | Beat | -28.0% | 20 | 2 up, 2 down | Oct 21, 2025 | $50.71B |
| Jun 30, 2025 | $8.84 | $8.92 | $8.70 - $9.98 | -0.90% | Miss | -12.6% | 19 | 0 up, 7 down | Jul 17, 2025 | $49.78B |
| Mar 31, 2025 | $11.97 | $11.48 | $10.58 - $11.85 | +4.27% | Beat | +12.5% | 18 | 9 up, 0 down | Apr 22, 2025 | $48.89B |
| Dec 31, 2024 | $3.84 | $3.85 | $3.77 - $3.97 | -0.26% | Miss | -31.7% | 17 | 0 up, 1 down | Jan 23, 2025 | $45.44B |
| Sep 30, 2024 | $8.37 | $9.65 | $9.17 - $10.19 | -13.26% | Miss | -6.9% | 19 | 1 up, 1 down | Oct 17, 2024 | $45.15B |
| Jun 30, 2024 | $10.12 | $10.01 | $9.82 - $10.27 | +1.10% | Beat | +11.9% | 20 | 0 up, 1 down | Jul 17, 2024 | $43.65B |
| Mar 31, 2024 | $10.64 | $10.53 | $10.17 - $11.07 | +1.04% | Beat | +12.5% | 18 | 2 up, 0 down | Apr 18, 2024 | $42.58B |
| Dec 31, 2023 | $5.62 | $5.59 | $5.51 - $6.48 | +0.54% | Beat | +7.5% | 14 | 2 up, 0 down | Jan 24, 2024 | $42.65B |
| Sep 30, 2023 | $8.99 | $8.46 | $8.07 - $8.65 | +6.26% | Beat | +19.4% | 18 | 2 up, 0 down | Oct 18, 2023 | $42.85B |
| Jun 30, 2023 | $9.04 | $8.78 | $8.45 - $8.99 | +2.96% | Beat | +12.4% | 20 | 0 up, 1 down | Jul 19, 2023 | $43.67B |
| Mar 31, 2023 | $9.46 | $9.28 | $8.96 - $9.45 | +1.94% | Beat | +14.7% | 19 | 2 up, 1 down | Apr 19, 2023 | $42.17B |
| Dec 31, 2022 | $5.23 | $5.19 | $5.12 - $5.27 | +0.77% | Beat | +1.8% | 20 | 0 up, 2 down | Jan 25, 2023 | $39.93B |
| Sep 30, 2022 | $7.53 | $7.15 | $6.83 - $7.26 | +5.31% | Beat | +10.9% | 19 | 2 up, 3 down | Oct 19, 2022 | $39.94B |
| Jun 30, 2022 | $8.04 | $7.74 | $7.38 - $7.92 | +3.88% | Beat | +14.4% | 20 | 2 up, 0 down | Jul 20, 2022 | $38.63B |
| Mar 31, 2022 | $8.25 | $7.83 | $7.26 - $8.31 | +5.36% | Beat | +17.7% | 19 | 3 up, 0 down | Apr 20, 2022 | $38.09B |
| Dec 31, 2021 | $5.14 | $5.12 | $4.99 - $5.68 | +0.39% | Beat | +102.4% | 22 | 0 up, 0 down | Jan 26, 2022 | $36.58B |
| Sep 30, 2021 | $6.79 | $6.37 | $5.81 - $6.93 | +6.59% | Beat | +61.7% | 20 | N/A | Oct 20, 2021 | $35.82B |
| Jun 30, 2021 | $7.03 | $6.34 | $6.12 - $6.55 | +10.88% | Beat | -23.6% | 21 | N/A | Jul 21, 2021 | $33.85B |
| Mar 31, 2021 | $7.01 | $6.47 | $5.82 - $7.83 | +8.35% | Beat | +8.2% | 18 | N/A | Apr 21, 2021 | $32.38B |
| Dec 31, 2020 | $2.54 | $2.53 | $2.40 - $3.01 | +0.40% | Beat | -34.5% | 19 | N/A | Jan 27, 2021 | $31.82B |
| Sep 30, 2020 | $4.20 | $4.18 | $3.77 - $4.71 | +0.48% | Beat | -13.8% | 22 | N/A | Oct 28, 2020 | $31.16B |
| Jun 30, 2020 | $9.20 | $8.58 | $6.04 - $9.31 | +7.23% | Beat | +98.3% | 22 | N/A | Jul 29, 2020 | $29.26B |
| Mar 31, 2020 | $6.48 | $6.44 | $6.25 - $7.12 | +0.62% | Beat | +7.5% | 17 | N/A | Apr 29, 2020 | $29.62B |
| Dec 31, 2019 | $3.88 | $3.89 | $3.83 - $4.07 | -0.26% | Miss | +59.0% | 23 | N/A | Jan 29, 2020 | $27.41B |
| Sep 30, 2019 | $4.87 | $4.82 | $4.64 - $5.03 | +1.04% | Beat | +27.8% | 22 | N/A | Oct 23, 2019 | $26.67B |
| Jun 30, 2019 | $4.64 | $4.62 | $4.50 - $4.86 | +0.43% | Beat | +9.2% | 21 | N/A | Jul 24, 2019 | $25.47B |
| Mar 31, 2019 | $6.03 | $5.90 | $5.05 - $6.87 | +2.20% | Beat | +11.5% | 21 | N/A | Apr 24, 2019 | $24.67B |
| Dec 31, 2018 | $2.44 | $2.20 | $2.13 - $2.35 | +10.91% | Beat | +89.1% | 21 | N/A | Jan 30, 2019 | $23.37B |
| Sep 30, 2018 | $3.81 | $3.70 | $3.41 - $4.07 | +2.97% | Beat | +43.8% | 21 | N/A | Oct 31, 2018 | $23.25B |
| Jun 30, 2018 | $4.25 | $4.18 | $3.75 - $4.40 | +1.67% | Beat | +26.1% | 20 | N/A | Jul 25, 2018 | $22.94B |
| Mar 31, 2018 | $5.41 | $4.89 | $4.58 - $5.22 | +10.63% | Beat | +15.6% | 18 | N/A | Apr 25, 2018 | $22.54B |
| Dec 31, 2017 | $1.29 | $1.27 | $1.16 - $1.51 | +1.57% | Beat | -26.7% | 20 | N/A | Jan 31, 2018 | $22.68B |
| Sep 30, 2017 | $2.65 | $2.40 | $2.24 - $2.57 | +10.42% | Beat | +8.2% | 15 | N/A | Oct 25, 2017 | $22.43B |
| Jun 30, 2017 | $3.37 | $3.24 | $2.90 - $3.48 | +4.01% | Beat | +1.2% | 19 | N/A | Jul 26, 2017 | $22.41B |
| Mar 31, 2017 | $4.68 | $3.81 | N/A | +22.83% | Beat | +35.3% | N/A | N/A | Apr 26, 2017 | $22.53B |
| Dec 31, 2016 | $1.76 | $1.76 | N/A | 0.00% | In line | +54.4% | N/A | N/A | Feb 1, 2017 | $21.71B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $30.17, down 8.5% from the year before. It was $11.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $30.17 | -8.5% |
| Dec 31, 2024 | $32.97 | -0.4% |
| Dec 31, 2023 | $33.11 | +14.0% |
| Dec 31, 2022 | $29.05 | +11.9% |
| Dec 31, 2021 | $25.97 | +15.8% |
| Dec 31, 2020 | $22.42 | +15.4% |
| Dec 31, 2019 | $19.42 | +22.1% |
| Dec 31, 2018 | $15.91 | +32.7% |
| Dec 31, 2017 | $11.99 | +9.0% |
| Dec 31, 2016 | $11.00 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,700 words across 23 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,748 | 23 | |
| 2026Q2 | Jun 30, 2026 | 7,428 | 22 | |
| 2026Q1 | Mar 31, 2026 | 7,144 | 24 | |
| 2025Q4 | Dec 31, 2025 | 2,295 | 9 | |
| 2025Q3 | Sep 30, 2025 | 9,088 | 21 | |
| 2025Q2 | Jun 30, 2025 | 7,606 | 23 | |
| 2025Q1 | Mar 31, 2025 | 6,906 | 22 | |
| 2024Q4 | Dec 31, 2024 | 8,716 | 23 |
2026Q3 Earnings Call
Opening remarks
Nathan Rich Vice President of Investor Relations Good morning, and welcome to Elevance Health's third quarter 2026 earnings conference call. My name is Nathan Rich, Vice President of Investor Relations. With us today on the earnings call are Gail Boudreaux, President and CEO, Mark Kaye, our CFO, Felicia Norwood, our Chief Health Benefits Officer, and Morgan Kendrick, President of our Commercial Health Benefits business. Gail will highlight our third quarter performance and discuss the progress we're making on our strategic priorities. Mark will then discuss our financial results and the drivers supporting our earnings outlook in greater detail. After our prepared remarks, the team will be available for a question-and-answer session. During the call, we will reference certain non-GAAP financial measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website, elevancehealth.com. We will also be making forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Elevance Health. These risks and uncertainties may cause actual results to differ materially from our current expectations, and we advise listeners to carefully review the risk factors discussed in today's press release and in our quarterly filings with the SEC. I will now turn the call over to Gail.
Gail Boudreaux President and CEO Good morning, and thank you for joining us. Elevance Health delivered strong third quarter results, with Medicaid, Medicare Advantage, and Individual ACA each contributing to our better-than-expected performance. These results reflect focused execution across the enterprise. They support a higher earnings outlook for 2026 and increase our confidence in the sustainability of our performance entering 2027. We are revising our 2026 adjusted diluted earnings per share guidance to at least $29, reflecting operating outperformance as well as favorable non-operating items. More importantly, we're raising our 2026 earnings baseline to at least $26.75. That increase reflects better underlying results and greater confidence in the durability of that performance. From this higher baseline, we remain confident in our ability to deliver at least 12% adjusted diluted earnings per share growth in 2027. We expect that growth to be driven by continued margin improvement in Health Benefits, broader adoption of Carelon's value-based solutions, and greater operating efficiency across the enterprise. We are bringing together the scale and local presence of our Health Benefits business with Carelon's clinical and operational expertise to improve outcomes and make care more affordable. As we extend these solutions across our health plans and to external clients, we expect to improve medical cost management, increase operating leverage, and deliver greater value for those we serve. We are already seeing measurable results.
Frequently Asked Questions About ELV
When is Elevance Health's next earnings date?
Elevance Health's next earnings report is expected for Jan 26, 2027.
Did ELV beat earnings estimates last quarter?
Yes. Elevance Health reported EPS of $6.99 for the quarter ended Sep 30, 2026, above the $4.66 estimate, a 50.00% surprise.
What EPS do analysts expect from ELV next quarter?
The consensus EPS estimate for Elevance Health for the quarter ending Dec 31, 2026 is $2.08 from 23 analysts, with estimates from $1.61 to $3.38.
How often does ELV beat earnings estimates?
Elevance Health beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +14.98%.
ELV pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts